BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16382039)

  • 21. A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status.
    Zipser MC; Eichhoff OM; Widmer DS; Schlegel NC; Schoenewolf NL; Stuart D; Liu W; Gardner H; Smith PD; Nuciforo P; Dummer R; Hoek KS
    Pigment Cell Melanoma Res; 2011 Apr; 24(2):326-33. PubMed ID: 21176117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy and targeted therapy combinations in advanced melanoma.
    Flaherty KT
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2366s-2370s. PubMed ID: 16609060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
    Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP
    Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KIT pathway alterations in mucosal melanomas of the vulva and other sites.
    Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
    Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
    Ogawa K; Sun C; Horii A
    Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
    Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA
    Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospects for non-immunological molecular therapeutics in melanoma.
    Eustace AJ; Mahgoub T; Tryfonopoulos D; O'Donovan N; Crown J
    J BUON; 2010; 15(1):9-18. PubMed ID: 20414921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular drivers of cellular metabolic reprogramming in melanoma.
    Abildgaard C; Guldberg P
    Trends Mol Med; 2015 Mar; 21(3):164-71. PubMed ID: 25618774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding signaling cascades in melanoma.
    Lopez-Bergami P; Fitchman B; Ronai Z
    Photochem Photobiol; 2008; 84(2):289-306. PubMed ID: 18086245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perspectives in melanoma treatment with signal transduction.
    La Porta CA
    Curr Med Chem Anticancer Agents; 2002 May; 2(3):371-85. PubMed ID: 12678738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melanoma: targeting signaling pathways and RaLP.
    Pasini L; Turco MY; Luzi L; Aladowicz E; Fagiani E; Lanfrancone L
    Expert Opin Ther Targets; 2009 Jan; 13(1):93-104. PubMed ID: 19063709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Embryonic signaling in melanoma: potential for diagnosis and therapy.
    Strizzi L; Hardy KM; Kirsammer GT; Gerami P; Hendrix MJ
    Lab Invest; 2011 Jun; 91(6):819-24. PubMed ID: 21464823
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Revisiting the melanomagenic pathways and current therapeutic approaches.
    Dhanyamraju PK; Rotimi S; Bhattacharya P; Patel TN
    Mol Biol Rep; 2022 Oct; 49(10):9651-9671. PubMed ID: 35397763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular biology of human melanoma development and progression.
    Sauter ER; Herlyn M
    Mol Carcinog; 1998 Nov; 23(3):132-43. PubMed ID: 9833774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From simplicity to complexity in current melanoma models.
    Michielon E; de Gruijl TD; Gibbs S
    Exp Dermatol; 2022 Dec; 31(12):1818-1836. PubMed ID: 36103206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Embedded Spheroids as Models of the Cancer Microenvironment.
    Tevis KM; Colson YL; Grinstaff MW
    Adv Biosyst; 2017 Oct; 1(10):. PubMed ID: 30221187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ROCK inhibitor enhances the growth and migration of BRAF-mutant skin melanoma cells.
    Chang F; Zhang Y; Mi J; Zhou Q; Bai F; Xu X; Fisher DE; Sun Q; Wu X
    Cancer Sci; 2018 Nov; 109(11):3428-3437. PubMed ID: 30168234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer diagnostics: The journey from histomorphology to molecular profiling.
    Ahmed AA; Abedalthagafi M
    Oncotarget; 2016 Sep; 7(36):58696-58708. PubMed ID: 27509178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancing the evaluation of PI3K inhibitors through 3D melanoma models.
    Shannan B; Chen Q; Watters A; Perego M; Krepler C; Thombre R; Li L; Rajan G; Peterson S; Gimotty PA; Wilson M; Nathanson KL; Gangadhar TC; Schuchter LM; Weeraratna AT; Herlyn M; Vultur A
    Pigment Cell Melanoma Res; 2016 May; 29(3):317-28. PubMed ID: 26850518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic interventions to disrupt the protein synthetic machinery in melanoma.
    Kardos GR; Robertson GP
    Pigment Cell Melanoma Res; 2015 Sep; 28(5):501-19. PubMed ID: 26139519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.